Tytuł pozycji:
Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia.
-
Tytuł:
-
Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia.
-
Autorzy:
-
Tarlock K; Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, WA.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Alonzo T; University of Southern California Keck School of Medicine, Los Angeles, CA.; Children's Oncology Group, Monrovia, CA; and.
Wang YC; Children's Oncology Group, Monrovia, CA; and.
Gerbing RB; Children's Oncology Group, Monrovia, CA; and.
Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Hylkema T; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Smith JL; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Maxson JE; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
-
Źródło:
-
Blood [Blood] 2020 Apr 30; Vol. 135 (18), pp. 1603-1606.
-
Typ publikacji:
-
Letter; Research Support, N.I.H., Extramural
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2021- : [New York] : Elsevier
Original Publication: New York, Grune & Stratton [etc.]
-
MeSH Terms:
-
Mutation*
Leukemia, Myeloid, Acute/*genetics
Leukemia, Myeloid, Acute/*mortality
Receptors, Colony-Stimulating Factor/*genetics
Alleles ; Biomarkers, Tumor ; Child ; Cytogenetic Analysis ; Genomics/methods ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/therapy ; Prognosis ; Survival Analysis
-
References:
-
Exp Hematol. 2017 Feb;46:9-20. (PMID: 27789332)
Br J Haematol. 2015 Aug;170(3):391-7. (PMID: 25858548)
Haematologica. 2017 Jun;102(6):e238-e240. (PMID: 28302714)
Blood. 2004 May 1;103(9):3305-12. (PMID: 14656892)
Nat Commun. 2019 Nov 29;10(1):5455. (PMID: 31784538)
Leukemia. 2013 Sep;27(9):1870-3. (PMID: 23604229)
Blood. 2016 Jun 16;127(24):3094-8. (PMID: 27143256)
Oncotarget. 2018 Jan 3;9(38):24970-24979. (PMID: 29861846)
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2985-8. (PMID: 7512720)
Nat Med. 2018 Jan;24(1):103-112. (PMID: 29227476)
Leukemia. 2001 May;15(5):779-86. (PMID: 11368439)
Blood. 2009 Jun 25;113(26):6558-66. (PMID: 19304957)
Blood. 2012 May 31;119(22):5071-7. (PMID: 22371884)
Cell Rep. 2014 Sep 25;8(6):1974-1988. (PMID: 25242324)
N Engl J Med. 2013 May 9;368(19):1781-90. (PMID: 23656643)
Blood. 1994 Sep 15;84(6):1737-46. (PMID: 7521686)
Blood. 2016 Jun 16;127(24):3054-61. (PMID: 27034432)
Ann Hematol. 2019 Jul;98(7):1641-1646. (PMID: 31041512)
Blood. 2013 Nov 21;122(22):3628-31. (PMID: 24081659)
Blood. 2007 Jan 1;109(1):93-9. (PMID: 16985178)
Blood. 2013 Aug 29;122(9):1576-82. (PMID: 23863898)
Blood. 2014 Apr 3;123(14):2229-37. (PMID: 24523240)
Blood Cancer J. 2012 Aug 31;2:e86. (PMID: 22941341)
Cancer. 2018 Aug;124(16):3329-3338. (PMID: 29932212)
-
Grant Information:
-
R01 CA114563 United States CA NCI NIH HHS; U10 CA180886 United States CA NCI NIH HHS; U10 CA180899 United States CA NCI NIH HHS
-
Substance Nomenclature:
-
0 (Biomarkers, Tumor)
0 (CSF3R protein, human)
0 (Receptors, Colony-Stimulating Factor)
-
Entry Date(s):
-
Date Created: 20200319 Date Completed: 20201221 Latest Revision: 20210430
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7193184
-
DOI:
-
10.1182/blood.2019004179
-
PMID:
-
32187354
-